Lantheus reiterates $1.4B-$1.45B 2026 revenue outlook while targeting PYLARIFY TRUVU transition in Q4
Lantheus Holdings, Inc · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $97.13
+3.7% in 3d after detection
Post-detection moves
1h
—
1d
+1.1%
3d
+3.7%
7d
-0.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS